| Date Filed | Type | Description |
| 02/03/2023 |
SC 13G/A
| Jemapete Christopher J reports a 6.2% stake in GENE BIOTHERAPEUTICS, INC. |
| 03/30/2022 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 10/27/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 09/17/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
| 09/03/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
| 08/09/2021 |
8-K/A
| Quarterly results |
| 08/05/2021 |
8-K
| Changes in Registrant's Certifying Accountant |
| 07/28/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/28/2021 |
SC 13G
| Jemapete Christopher J reports a 8.1% stake in GENE BIOTHERAPEUTICS, INC. |
| 04/26/2021 |
8-K
| Quarterly results |
| 04/23/2021 |
10-K
| Annual Report for the period ended December 31, 2019 |
| 03/18/2021 |
SC 13D/A
| Jemapete Christopher J reports a 27.6% stake in GENE BIOTHERAPEUTICS, INC. |
| 03/01/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 12/22/2020 |
SC 13G
| Coluccio Christian F reports a 5% stake in Gene Biotherapeutics, Inc. |
| 06/01/2020 |
SC 13D
| Nostrum Pharmaceuticals, LLC reports a 91.2% stake in GENE BIOTHERAPEUTICS, INC. |
| 05/28/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock",
"Preferred Stock Purchase Agreement for the purchase of Series B Convertible Preferred Stock",
"Reaffirmation and Ratification Agreement between Gene Biotherapeutics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd",
"Distribution and License Agreement between Angionetics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd",
"Amendment No. 1 to Distribution and License Agreement between Angionetics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd",
"License and Patent Assignment Agreement between Activation Therapeutics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd",
"GENE BIOTHERAPEUTICS SECURES INVESTMENT FROM NOSTRUM PHARMACEUTICALS, LLC" |
|
| 03/20/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/22/2019 |
SC 13D
| Rothenburg Barry reports a 11.2% stake in GENE BIOTHERAPEUTICS INC. |
| 12/04/2018 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 09/13/2018 |
8-K
| Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits |
| 05/16/2018 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 01/09/2018 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 01/04/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/15/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/15/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/28/2017 |
10-Q
| Quarterly Report for the period ended March 31, 2017 |
| 07/28/2017 |
10-K
| Annual Report for the period ended December 31, 2016 |
| 05/16/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 03/30/2017 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 03/21/2017 |
10-Q
| Quarterly Report for the period ended September 30, 2016 |
| 03/06/2017 |
10-Q
| Quarterly Report for the period ended June 30, 2016 |
| 03/01/2017 |
10-Q
| Quarterly Report for the period ended March 31, 2016 |
| 01/10/2017 |
8-K
| Quarterly results |
| 01/05/2017 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
|